Rhabdomyosarcoma: Symptoms, Diagnosis, and Treatment

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and adolescents, accounting for a disproportionate share of childhood cancer diagnoses despite being rare overall. It resembles developing skeletal muscle under the microscope, yet it can appear almost anywhere in the body, including places where skeletal muscle does not normally exist. Because its symptoms often mimic everyday childhood ailments, catching it early requires a degree of suspicion that most parents and even some clinicians do not initially have.

Who Gets Rhabdomyosarcoma

RMS overwhelmingly affects children and teenagers. The overall incidence is roughly 4 to 5 cases per million children per year, with boys outnumbering girls by about three to two.¹ That male predominance is driven almost entirely by the embryonal subtype, the most common form, which peaks in children under five and shows a smaller secondary peak in adolescence.²

Adults can develop RMS too, though the disease looks different in that population. A large analysis comparing over a thousand adult patients to roughly 1,500 children found that adult tumors were more likely to occur at unfavorable sites and to have histologic subtypes rarely seen in children, particularly the pleomorphic subtype.³ The practical takeaway is that RMS in adults tends to behave more aggressively and responds less predictably to the treatment playbook developed for children.

Subtypes and Why They Matter

RMS is classified into four main subtypes, each with distinct microscopic features and genetic fingerprints: embryonal, alveolar, spindle cell/sclerosing, and pleomorphic.⁴ For most families, the two that matter most are embryonal and alveolar, which together make up the vast majority of childhood cases. In one large population-based study, embryonal RMS accounted for about two-thirds of pediatric cases and alveolar for roughly a third.¹

Embryonal RMS generally carries a better prognosis. It tends to arise in the head and neck region or the genitourinary tract, and it peaks in young children. Alveolar RMS, by contrast, distributes more evenly across age groups and is more likely to appear in the extremities. The distinction matters because it directly shapes treatment intensity and predicted outcomes.

Symptoms by Location

RMS symptoms are notoriously variable because the tumor can arise in so many different body sites. The three most common locations are the head and neck, the genitourinary tract, and the extremities, and each presents differently.

Head and neck tumors make up a large share of childhood RMS. When the tumor is in the orbit (the eye socket), it typically causes the eye to bulge forward and sometimes restricts eye movement. When it grows from a parameningeal site, such as the middle ear, nasal cavity, or sinuses, the first signs are often nasal obstruction or a discharge that may be blood-tinged. Tumors in other parts of the head and neck frequently show up as a painless mass that slowly enlarges.⁵

Genitourinary RMS often starts in the bladder or prostate in boys, producing blood in the urine or difficulty urinating. Prostate tumors can grow large enough to press on the bladder or bowel, causing frequent urination or constipation. In girls, vaginal tumors tend to appear in very young children and cause a blood-tinged vaginal discharge. Paratesticular tumors show up as painless swelling in the scrotum or groin.⁵

Extremity RMS typically appears in adolescents as a painful mass or swelling, sometimes with redness of the skin above it. These tumors are especially worrisome because close to half are the alveolar subtype and they are more prone to spreading to lymph nodes and along tissue planes.⁵

Why Diagnosis Is Often Delayed

One of the most frustrating aspects of RMS is that early symptoms commonly masquerade as everyday childhood problems. A bladder or prostate tumor can look like a stubborn urinary tract infection. A sinus tumor can be mistaken for chronic sinusitis. A case series of children with bladder and prostate RMS showed that initial symptoms mimicked urinary tract infections, functional disorders, or congenital urinary abnormalities, and that proper diagnosis was delayed because no imaging was performed for weeks despite atypical or severe symptoms.⁶

The problem is compounded by several system-level factors. Research into diagnostic delays in pediatric cancers found that the type of doctor initially consulted, the specialty of that doctor, the number of additional visits before referral, and the child’s age and presenting symptom all influenced how long it took to reach the right diagnosis.⁷ For parents, the practical lesson is straightforward: if a child has a recurrent or atypical infection, a mass that does not resolve, or unexplained bleeding from the nose, ear, or genitourinary tract, pushing for imaging sooner rather than later can make a real difference.

How the Diagnosis Is Confirmed

Confirming RMS requires a tissue biopsy. Under the microscope, the tumor cells resemble immature skeletal muscle, but that appearance can overlap with other childhood cancers. Pathologists rely on a panel of immunohistochemistry markers to nail down the diagnosis. The key markers are desmin, MyoD1, and myogenin, all of which are proteins linked to muscle development. In one study, every RMS specimen was positive for MyoD1, including cases that failed to stain for desmin, suggesting that MyoD1 picks up cases desmin alone would miss.⁸ Newer antibody clones have improved sensitivity further, with one study finding that a particular MyoD1 clone achieved nuclear staining in all 21 RMS cases tested.⁹

Beyond confirming that the tumor is RMS, pathologists now test for a specific genetic rearrangement: a fusion between the FOXO1 gene and either PAX3 or PAX7. This fusion is the hallmark of the alveolar subtype and has become the single most important molecular marker in the disease, as we’ll see below in staging.

Staging and the Role of FOXO1 Fusion Status

Once the diagnosis is made, the team stages the disease to determine how far it has spread and assigns a risk group to guide treatment intensity. Traditional staging relies on the tumor’s primary site, its size, whether it has been fully removed surgically, whether lymph nodes are involved, and whether distant spread has occurred. But over the past decade, FOXO1 fusion status has emerged as a game-changer in risk stratification.

Among patients with localized disease, those who are PAX3/FOXO1 fusion-positive have significantly worse outcomes compared with both fusion-negative patients and those carrying the PAX7/FOXO1 variant.¹⁰ A meta-analysis found indications that PAX3-FOXO1 carried a lower survival probability than PAX7-FOXO1, though the effect fell just short of traditional statistical significance.¹¹ Several favorable clinical features, including age between one and nine years, complete surgical removal, tumor size under five centimeters, a favorable primary site, and the PAX7-FOXO1 fusion specifically, were all associated with better outcomes in a Children’s Oncology Group analysis of fusion-positive patients.¹²

Current European and North American clinical trials now formally incorporate FOXO1 fusion status into their risk stratification schemes. A recent European reappraisal of prognostic factors retained five variables in its final model: age at diagnosis interacting with tumor size, primary tumor site, clinical group, and FOXO1 fusion status, and used those to stratify patients into four risk tiers with a scoring nomogram.¹³ The Children’s Oncology Group has likewise endorsed the addition of fusion status to traditional clinical predictors.¹⁴

Imaging for Staging

Staging workup typically involves a mix of imaging studies to check for distant spread. PET-CT has gained ground as the preferred tool. A Children’s Oncology Group comparison found that PET-CT outperformed conventional imaging for detecting disease in lymph nodes, bone, bone marrow, and soft tissue, though conventional CT remained essential for spotting small lung nodules.¹⁵ A European study confirmed these findings: PET-CT was more sensitive than standard imaging for locoregional lymph nodes and bone metastases but less sensitive for lung lesions. In a small but meaningful fraction of patients, PET-CT upstaged the disease from localized to metastatic, directly changing the treatment plan.¹⁶

Treatment Overview

RMS treatment is multimodal, combining chemotherapy with local control measures (surgery, radiation, or both). The backbone chemotherapy regimen in North America is VAC: vincristine, actinomycin D, and cyclophosphamide.¹⁷ European protocols use a similar combination, substituting ifosfamide for cyclophosphamide in some settings. A key Children’s Oncology Group trial compared standard VAC against an alternating regimen that swapped in vincristine, topotecan, and cyclophosphamide for some cycles. At about four years of follow-up, the experimental arm showed no improvement, with failure-free survival of roughly 68% versus 73% on standard VAC.¹⁸

For local control, the approach depends on the tumor’s site and how completely it can be removed. Evidence-based surgical guidelines recommend aiming for a resection margin of at least half a centimeter, performing pretreatment re-excision for incompletely removed tumors, and marking the tumor bed with surgical clips to guide later radiation.¹⁹ When the tumor cannot be removed up front, radiation is used alongside chemotherapy to control it locally, with surgery sometimes reconsidered after the tumor shrinks.

Proton Therapy and Sparing Growing Tissues

Radiation is a critical piece of RMS treatment, but in children, whose bodies are still developing, minimizing radiation to healthy surrounding tissue is paramount. This is where proton beam therapy has become an important option. Unlike conventional photon radiation, protons deposit most of their energy at a specific depth and then stop, sharply reducing the dose to tissues beyond the tumor.

A dosimetric study of pediatric RMS patients found that proton therapy cut the average integral radiation dose to the body by roughly half compared with intensity-modulated photon radiation, and the sparing was even more dramatic for orbital tumors, where protons delivered about 3.5 times less integral dose.²⁰ An earlier study specifically of orbital RMS confirmed that proton therapy offered meaningful advantages in limiting dose to the brain, pituitary gland, and structures of both eyes.²¹ A follow-up of children treated with pencil beam scanning proton therapy found that quality-of-life scores, initially worse than those of healthy peers, largely normalized over time, with children rating their body image even higher than the general population by the later assessment.²²

Proton therapy is not available everywhere, and it tends to be more expensive. But for tumors near sensitive structures, especially in the head, orbit, or pelvis of a young child, the reduction in long-term side effects makes it a strong consideration when accessible.

When the Disease Comes Back

Relapse remains one of the most challenging scenarios in RMS. How well a child fares after recurrence depends heavily on several factors: the original risk group, how soon the relapse occurred, and whether a second complete remission can be achieved.²³

European registry data illustrate the disparity starkly. For children whose initial disease was classified as standard risk, five-year survival after relapse was about 80%. For those who started in the high-risk group, it dropped to roughly 20%, and for the very-high-risk group, it fell further still.²⁴ A separate French series of children with relapsed localized RMS found a somewhat more hopeful overall picture: about 40% responded to second-line chemotherapy, roughly 60% achieved a second complete remission after combining chemotherapy with delayed surgery or radiation, and five-year survival after relapse reached nearly 50%.²⁵

These numbers underscore why accurate initial risk stratification matters so much. A child whose tumor is correctly identified as high-risk from the start gets more aggressive upfront therapy, and that intensity is the best chance at preventing relapse in the first place.

Long-Term Effects for Survivors

Surviving RMS is only half the story. Because treatment involves potent chemotherapy and often radiation to growing tissues, survivors carry elevated risks of a range of late effects for years after they finish therapy. A large Childhood Cancer Survivor Study analysis found that RMS survivors had significantly higher rates of numerous conditions compared with their siblings more than five years after diagnosis. The relative risks were especially elevated for growth hormone deficiency, the need for medications to trigger puberty, congestive heart failure, cataracts, legal blindness, and motor problems.²⁶

Separately, a study focused specifically on neurocognitive and emotional outcomes found that survivors reported more difficulty with task efficiency, emotional regulation, and memory compared with their siblings. They also showed higher rates of depression, anxiety, and somatic distress, and poorer physical and social functioning.²⁷ These are not rare outliers; more than one in five survivors reported depressive symptoms, and similar proportions reported problems with vitality and pain.

Long-term follow-up clinics, now standard at most pediatric cancer centers, screen survivors for these complications and intervene early, whether that means hormone replacement, cardiac monitoring, vision assessments, or mental health support. Families should expect that follow-up care extends well into adulthood.

Where Does the Tumor Actually Come From

One of the stranger puzzles in RMS biology is that a tumor defined by its resemblance to skeletal muscle routinely shows up in places where skeletal muscle does not exist, such as the bladder, the biliary tract, or the orbit. For decades, the assumption was that every RMS arose from wayward skeletal muscle precursors, but newer research has upended that idea.

Investigators demonstrated that RMS can arise from endothelial progenitor cells, the precursors of blood vessel lining, after those cells undergo reprogramming and switch their developmental fate toward muscle.²⁸ Follow-up work using lineage tracing in mice pinpointed a narrow window during embryonic development when a specific subset of endothelial progenitor cells could be coaxed into becoming RMS, and the transformation depended on whether those cells still had the cellular machinery to respond to a particular signaling pathway.²⁹

This line of research is still in its early stages, but it has real implications. If RMS can start from more than one cell type, then different tumors that look identical under the microscope could have different vulnerabilities. That insight could eventually open up new treatment strategies tailored not just to what the tumor looks like but to what it actually started as. It also offers a tidy explanation for why tumors crop up in muscle-free zones: the cell of origin was never a muscle cell to begin with.

Emerging Molecular Targets

Chemotherapy regimens for RMS have improved survival substantially over the past few decades, but they have largely plateaued. Ongoing research is trying to move beyond the same three or four drugs by identifying molecular weak spots in the tumor. An integrated genomic and proteomic analysis identified deregulation of specific cell-growth and stress-response pathways in RMS, providing new potential drug targets.³⁰ Inhibitors targeting some of these pathways are already in clinical trials for other cancers and could be repurposed. Whether they will meaningfully improve outcomes for RMS patients remains to be seen, but the shift from purely cytotoxic chemotherapy toward molecularly targeted therapy represents the direction the field is heading.